Advertisement

Topics

Durvalumab granted breakthrough designation by FDA for locally advanced unresectable NSCLC

05:16 EDT 1 Aug 2017 | ecancermedicalscience

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for durvalumab), an anti-PD-L1 monoclonal antibody, being investigated for the treatment of patients with locally advanced, unresectable non-small cell lung cancer...

Original Article: Durvalumab granted breakthrough designation by FDA for locally advanced unresectable NSCLC

NEXT ARTICLE

More From BioPortfolio on "Durvalumab granted breakthrough designation by FDA for locally advanced unresectable NSCLC"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...